Comparative cost-effectiveness analysis of therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk or a history of atherosclerotic cardiovascular diseases in the Russian healthcare system
Open Access
- 18 January 2026
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (12) , 6687
Abstract
Aim . To conduct a comparative cost-effectiveness analysis of therapy with sodiumglucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists in patients with type 2 diabetes (T2D) and high cardiovascular risk in the Russian Federation. Material and methods. Given the comparable clinical efficacy of these drug classes for the major adverse cardiovascular events (MACE), as confirmed by systematic reviews, a cost-minimization approach was chosen for the analysis. Annual costs were calculated for agents from the list of vital and essential drugs for a target population of 2,74 million patients. Results. The average annual cost of therapy with SGLT2 inhibitors was RUB 29973,53 and was more than 2 times lower than the cost of therapy with GLP-1 agonists (RUB 66594,10). Using SGLT2 inhibitors across the entire target population will save RUB 100,33 billion per year (the costs of GLP-1 therapy are higher then 122%) with comparable clinical efficacy. Conclusion. Based on comparable clinical efficacy and significant cost advantage, SGLT2 inhibitors can be recommended as priority therapy in Russian clinical practice to reduce cardiovascular risk in patients with T2D.Keywords
This publication has 20 references indexed in Scilit:
- The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trialsDiabetologia, 2021
- Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetesEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2021
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysisThe Lancet Diabetes & Endocrinology, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015